Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
Shinya MaekawaMitsuaki SatoNatsuhiko KuratomiTaisuke InoueYuichiro SuzukiAkihisa TatsumiMika MiuraShuya MatsudaMasaru MuraokaNatsuko NakakukiFumitake AmemiyaShinichi TakanoMitsuharu FukasawaYasuhiro NakayamaTatsuya YamaguchiTadashi SatoMinoru SakamotoMiyako MurakawaMina NakagawaYasuhiro AsahinaNobuyuki EnomotoPublished in: Journal of gastroenterology (2017)
Through the analysis we suggest that the A allele in UGT1A1 rs4148323 (UGT1A1*6), which is highly prevalent in the Japanese population, should be considered a risk for the development of DCV/ASV therapy-induced ALT elevation. Pretreatment SNP testing of UGT1A1*6 might be beneficial for the prediction of liver damage induced by DCV/ASV or even by DCV/ASV plus beclabuvir.